Apretude is a medicine approved by the FDA in 2021 to reduce the risk of contracting HIV through sexual contact, also known as pre-exposure prophylaxis (PrEP). PrEP is used to prevent the transmission ...
Apretude is a long-acting injectable medication used to prevent HIV (human immunodeficiency virus) infection in adults and some children who are at high risk of contracting the virus. Apretude is ...
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds ...
Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...
The application is supported by data from the phase 2b/3 HPTN 083 and HPTN 084 trials, which evaluated the efficacy and safety of Apretude for HIV PrEP. The Food and Drug Administration (FDA) has ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...
The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...
In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, seven participants contracted the virus despite receiving their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results